The Capital Injection: London-based bio-wearable developer Sava Technologies raises $36 million in a Series B round led by Ascensia Diabetes Care, bringing total funding to $68 million to advance clinical trials and scale automated micro-fabrication.
The Structural Shift: Sava's sub-dermal microsensors are approximately ten times shorter than conventional CGM sensor filaments. The design aims to reduce the extent of sensor insertion while maintaining continuous glucose mea
